- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04944550
New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract. (CICLOP)
Development of New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.
Upper Urinary Tract Urothelial Carcinomas are rare, aggressive tumors, accounting for 5 to 10% of all urothelial tumors. These include tumors which develop in the renal cavities (renal pelvis, calices) and ureteral tumors. Nephro-ureterectomy is the standard treatment but 80% of patients will have a relapse within 2 years. Only one trial has (Birtle et al. 2020), has shown the interest of postoperative chemotherapy. Neoadjuvant systemic treatment seems particularly interesting for a population which is going to undergo a nephronic loss and therefore reduction in kidney function which is likely to make patients ineligible for cisplatin. In favor of additional immunotherapy, it has been described that upper excretory tract tumors have a high immunogenic potential with a high rate of microsatellite instability.
From surgical samples of patient tumors obtained after nephroureterectomy or biopsy material collected before treatment, we are going to generate patient-derived cell lines and xenograft models in the mouse. A recent publication has demonstrated the feasibility of this approach by specifying that the capture rate of tumor cells is 50% for patient-derived xenografts and 25% for patient-derived cells (Coleman et al. 2020). As tumors harvested from biopsies do not grow in patient-derived xenografts,we plan to graft the biopsies onto chorioallantoic chicken embryo membranes, a model which has never been used for this indication and which is one of the original features of our approach. These three concomitant approaches will allow us to increase our chances of obtaining stable upper urinary tract urothelial carcinoma lines to be used for the screening and identification of new treatments or new combinations of molecules that would benefit patients with upper urinary tract urothelial carcinomas, knowing that very few studies dedicated to this type of cancer have been conducted or published due to the rarity of the disease and the lack of existing models published on the subject of these particular tumors.
.
연구 개요
상태
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: Nadine HOUEDE, Pr.
- 전화번호: +33 4.66.68.33.01
- 이메일: nadine.houede@chu-nimes.fr
연구 연락처 백업
- 이름: Anissa MEGZARI, Mme.
- 전화번호: 04.66.68.42.36
- 이메일: drc@chu-nimes.fr
연구 장소
-
-
Gard
-
Nîmes, Gard, 프랑스, 30029
- 모병
- Centre Hospitalier Universitaire de Nîmes
-
연락하다:
- Anissa MEZGARI
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Patients treated consecutively at the Urology Andrology Department of Nîmes University Hospital for high grade carcinoma of the pelvis or renal ureter with an indication for total nephroureterectomy decided during a multidisciplinary meeting.
- Patient with a diagnosis of high-grade urothelial carcinoma of the pelvis or renal ureter confirmed by histology (biopsy, biopsy of the ureteroscopic) or by cytology with the presence of :
- High-grade disease on ureteroscopic biopsy OR ;
- High grade disease on urinary cytology AND infiltrating appearance of the renal pelvic wall / ureter on the scanner (the presence of hydronephrosis will be considered as pervasive by definition) with a negative cytoscopy.
Exclusion Criteria:
- Any patient who has undergone previous systemic treatment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Histological characteristics of patient-derived xenograft models after staining.
기간: 1-6 months after harvesting
|
Microscopic observation of cells after staining with hematoxylin and eosin
|
1-6 months after harvesting
|
Study of genomes of tumor specimens
기간: 1-6 months after harvesting
|
Exome sequencing of DNA cells isolated from original patient tumor specimens.
|
1-6 months after harvesting
|
Alterations in the genomes of patient-derived xenograft tumor models
기간: 1-6 months after harvesting
|
Exome sequencing of DNA cells isolated from patient-derived xenograft tumor models.
|
1-6 months after harvesting
|
Alterations in the genomes of patient-derived cell line models
기간: 1-6 months after harvesting
|
Exome sequencing of DNA cells isolated from patient-derived cell line models.
|
1-6 months after harvesting
|
Study of the transcriptome of patient tumor specimens.
기간: 1-6 months after harvesting
|
RNA-sequencing of cells isolated from patient tumor specimens.
|
1-6 months after harvesting
|
Transcriptome of the patient-derived xenograft tumor models.
기간: 1-6 months after harvesting
|
RNA-sequencing of cells isolated from patient-derived xenograft tumor models.
|
1-6 months after harvesting
|
Transcriptome of the patient-derived cell line models.
기간: 1-6 months after harvesting
|
RNA-sequencing of cells isolated from patient-derived cell line models.
|
1-6 months after harvesting
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Sensitivity to Cisplatin: patient-derived cell line models
기간: 6-8 months after harvesting
|
The MIC 50 test (Minimum Inhibitory Concentration required for cell growth to be inhibited by 50%) will be used in vitro to test the tumor cells' response to Cisplatin.
|
6-8 months after harvesting
|
Sensitivity to Carboplatin: patient-derived cell line models
기간: 6-8 months after harvesting
|
The MIC 50 test (Minimum Inhibitory Concentration required for cell growth to be inhibited by 50%) will be used in vitro to test the tumor cells' response to Carboplatin.
|
6-8 months after harvesting
|
Sensitivity to Oxaliplatin: patient-derived cell line models
기간: 6-8 months after harvesting
|
The MIC 50 test (Minimum Inhibitory Concentration required for cell growth to be inhibited by 50%) will be used in vitro to test the tumor cells' response to Oxaliplatin.
|
6-8 months after harvesting
|
Sensitivity to Gemcitabin: patient-derived cell line models
기간: 6-8 months after harvesting
|
The MIC 50 test (Minimum Inhibitory Concentration required for cell growth to be inhibited by 50%) will be used in vitro to test the tumor cells' response to Gemcitabin.
|
6-8 months after harvesting
|
Tumor size in non-treated patient-derived xenograft models
기간: 1-6 months after harvesting
|
The volume of tumors will be measured in mm3.
|
1-6 months after harvesting
|
Sensitivity to Cisplatin: tumor size in treated patient-derived xenograft models
기간: 6-8 months after harvesting
|
To test the tumor cells' response to Cisplatin in xenograft models, the volume of tumors will be measured in mm3 and compared with the volume of tumors in the non-treated control group.
|
6-8 months after harvesting
|
Sensitivity to Cisplatin: tumor growth rate in patient-derived xenograft models
기간: 6-8 months after harvesting
|
To test the tumor cells' response to Cisplatin in xenograft models, the Tumor Growth Inhibition index, which is defined as (1 - (mean volume of treated tumors)/(mean volume of control tumors)) × 100% will be used.
|
6-8 months after harvesting
|
Sensitivity to Carboplatin: tumor size in treated patient-derived xenograft models
기간: 6-8 months after harvesting
|
To test the tumor cells' response to Carboplatin in xenograft models, the volume of tumors will be measured in mm3 and compared with the volume of tumors in the non-treated control group.
|
6-8 months after harvesting
|
Sensitivity to Carboplatin: tumor growth rate in treated patient-derived xenograft models
기간: 6-8 months after harvesting
|
To test the tumor cells' response to Carboplatin in xenograft models, the Tumor Growth Inhibition index, which is defined as (1 - (mean volume of treated tumors)/(mean volume of control tumors)) × 100% will be used.
|
6-8 months after harvesting
|
Sensitivity to Oxiplatin: tumor size in treated patient-derived xenograft models
기간: 6-8 months after harvesting
|
To test the tumor cells' response to Oxiplatin in xenograft models, the volume of tumors will be measured in mm and compared with the volume of tumors in the non-treated control group.
|
6-8 months after harvesting
|
Sensitivity to Oxiplatin: tumor growth rate in treated patient-derived xenograft models
기간: 6-8 months after harvesting
|
To test the tumor cells' response to Oxiplatin in xenograft models, the Tumor Growth Inhibition index, which is defined as (1 - (mean volume of treated tumors)/(mean volume of control tumors)) × 100% will be used.
|
6-8 months after harvesting
|
Sensitivity to Gemcitabine: tumor size in treated patient-derived xenograft models
기간: 6-8 months after harvesting
|
To test the tumor cells' response to Gemcitabine in xenograft models, the tumor volume will be measured in mm3 and compared with the volume of tumors in the non-treated control group.
|
6-8 months after harvesting
|
Sensitivity to Gemcitabin: tumor growth rate in treated patient-derived xenograft models
기간: 6-8 months after harvesting
|
To test the tumor cells' response to Gemcitabin in xenograft models, the Tumor Growth Inhibition index, which is defined as (1 - (mean volume of treated tumors)/(mean volume of control tumors)) × 100% will be used.
|
6-8 months after harvesting
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Patients' gender
기간: Day 0
|
The sex of patients will be recorded at the inclusion as Male/Female/Transgender
|
Day 0
|
Patients' age
기간: Day 0
|
The age of patients will be recorded at the inclusion in years
|
Day 0
|
Primitive tumor site
기간: Day 0
|
The site of the patient's primitive tumor will be recorded at the inclusion
|
Day 0
|
Infiltrative tumor
기간: Day 0
|
The tumor will be noted as infiltrative or not (YES/NO) at the inclusion.
|
Day 0
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Nadine HOUEDE, Pr., CHU de Nimes
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NIMAO/2020-2/NH01
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .